A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer

Prior treatment

• Patients receiving chemotherapy or hormonal therapy
• A prior or concurrent malignancy whose natural history or treatment would interfere with the toxicity or efficacy assessment of IVRT
• Prior pelvic radiotherapy
• Concurrent psychiatric or medical condition or disease which, per investigator judgement, would make them unsuitable candidates for study enrollment

Other illness

• Active genitourinary infection requiring antibiotics, except for uncomplicated urinary tract infection
• History of active inflammatory bowel disease requiring treatment, including Crohn's disease and ulcerative colitis

• Patients must be diagnosed with a primary endometrial carcinoma. The following histologic subtypes are eligible for inclusion: endometrioid, serious, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma
• Initial surgical treatment must have included hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node assessment with either sentinel lymph node mapping/sampling or pelvic lymph node dissection. Surgical assessment of the para-aortic lymph nodes is not required
• Patients must have had a complete surgical resection with negative margins and no residual gross disease after surgery
• Patients must have FIGO (2009) stage I-II disease (per surgical staging)
• Age ≥ 18 years
• Patients must be able to start radiotherapy within 12 weeks from date of surgery